The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of JNJ-55308942 in the Treatment of Bipolar Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05328297
Recruitment Status : Active, not recruiting
First Posted : April 14, 2022
Last Update Posted : May 22, 2024
Sponsor:
Information provided by (Responsible Party):
Janssen Pharmaceutica N.V., Belgium

Brief Summary:
The purpose of this study is to evaluate the efficacy of JNJ-55308942 compared to placebo on symptoms of depression in participants with bipolar disorder (BD) in a major depressive episode (MDE) at Week 6.

Condition or disease Intervention/treatment Phase
Bipolar Disorder Drug: JNJ-55308942 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 116 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression
Actual Study Start Date : June 3, 2022
Estimated Primary Completion Date : May 15, 2024
Estimated Study Completion Date : May 21, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bipolar Disorder

Arm Intervention/treatment
Experimental: JNJ-55308942
Participants will receive a JNJ-55308942 capsule once daily for 6 weeks.
Drug: JNJ-55308942
JNJ-55308942 capsules will be administered orally.

Placebo Comparator: Placebo
Participants will receive a matching placebo capsule once daily for 6 weeks.
Drug: Placebo
Matching placebo capsules will be administered orally.




Primary Outcome Measures :
  1. Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 [ Time Frame: Baseline and Week 6 ]
    Change from baseline in MADRS total score at Week 6 will be reported. The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.


Secondary Outcome Measures :
  1. Change from Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score at Week 6 [ Time Frame: Baseline and Week 6 ]
    Change from baseline in SHAPS total score at Week 6 will be reported.

  2. Change from Baseline in MADRS Total Score at Week 6 (Genetic Subgroup Analysis) [ Time Frame: Baseline and Week 6 ]
    Change from baseline in MADRS total score at Week 6 in participants who are heterozygous or homozygous for a specific single nucleotide polymorphism (SNP) (genetic subgroup analysis) will be reported.

  3. Change from Baseline in MADRS Total Score at Week 6 (Diagnosis Subgroup Analysis) [ Time Frame: Baseline and Week 6 ]
    Change from Baseline in MADRS total score at Week 6 in participants with bipolar disorder (BD) diagnostic subtypes (diagnosis subgroup analysis) will be reported.

  4. Change from Baseline in MADRS Total Score at Week 6 (Biomarker Subgroup Analysis) [ Time Frame: Baseline and Week 6 ]
    Change from baseline in MADRS total score at Week 6 in subgroups of participants with specific biomarker profiles (biomarker subgroup analysis) will be reported.

  5. Number of Participants with Abnormalities in Vital Signs [ Time Frame: Up to Week 8 ]
    Number of participants with abnormalities in vital signs (pulse/heart rate, systolic blood pressure [SBP], diastolic blood pressure [DBP], respiratory rate) will be reported.

  6. Number of Participants with Abnormalities in Clinical Laboratory Tests [ Time Frame: Up to Week 8 ]
    Number of participants with abnormalities in clinical laboratory tests (chemistry, hematology, urinalysis) will be reported.

  7. Number of Participants with Adverse Events (AEs) [ Time Frame: Up to Week 8 ]
    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

  8. Number of Participants with Abnormalities in Electrocardiograms (ECGs) [ Time Frame: Up to Week 8 ]
    Number of participants with abnormalities in ECG will be reported.

  9. Change from Baseline in Young Mania Rating Scale (YMRS) Score [ Time Frame: Baseline up to Week 6 ]
    Change from baseline in YMRS score will be reported. The YMRS is a rating scale used to assess manic symptoms.

  10. Change from Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) Score [ Time Frame: Baseline up to Week 8 ]
    Change from baseline in C-SSRS score will be reported.

  11. Change from Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score [ Time Frame: Baseline up to Week 6 ]
    Change from baseline in CGI-S scale score will be reported.

  12. Plasma Concentrations of JNJ-55308942 [ Time Frame: Days 1, 8, 15, 29, 43 ]
    Plasma samples will be analyzed to determine concentrations of JNJ-55308942 using a validated, specific, and sensitive liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) method.

  13. Change from Baseline in Patient Reported Outcome Measurement (PROMIS) Score - Ability to Participate in Social Roles and Activities Scores [ Time Frame: Baseline, up to Week 6 ]
    Change from baseline in PROMIS score- ability to participate in social roles and activity scores score will be reported. Participation in social roles and activities item bank assesses the perceived ability to perform one's usual social roles and activities.

  14. Change from Baseline in Patient Health Questionnaire (PHQ-9) Score [ Time Frame: Baseline up to Week 6 ]
    Change from baseline in PHQ-9 will be reported. PHQ-9 score used to assess the severity of depression in the participants.

  15. Change from Baseline in Generalized Anxiety Disorder 7 (GAD-7) Score. [ Time Frame: Baseline up to Week 6 ]
    Change from baseline in GAD-7 score will be reported.

  16. Percentage of Participants with Response at Week 6 [ Time Frame: Week 6 ]
    Percentage of participants with response (greater than or equal to [>=] 50 percent [%] improvement in MADRS total score) at Week 6 will be reported.

  17. Number of Participants with Remission at Week 6 [ Time Frame: Week 6 ]
    Number of participants with remission (MADRS total score less than or equal to [<=] 12) at Week 6 will be reported.

  18. Change from Baseline in MADRS Total Score at Week 6 (Subgroup of Participants with Messenger Ribonucleic Acid [mRNA] Transcript Levels) [ Time Frame: Baseline and Week 6 ]
    Change from baseline in MADRS total score at Week 6 in participants with levels of specific mRNA transcripts that exceed the median level will be reported.

  19. Change from Baseline in MADRS Total Score at Week 6 (Mood Stabilizer Subgroup Analysis) [ Time Frame: Baseline and Week 6 ]
    Change from baseline in MADRS total score at Week 6 in subgroup of participants with BD not taking any mood stabilizer or antipsychotic, taking a mood stabilizer alone, taking an antipsychotic alone, and taking a combination of a mood stabilizer and an antipsychotic (concomitant medication subgroup analysis) will be reported.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have a primary diagnostic and statistical manual of mental disorders (5th edition) (DSM-5) diagnosis of bipolar disorder (BD) (Type I or II) without current psychotic features, as confirmed by the mini international neuropsychiatric interview (MINI)
  • Medically stable on the basis of physical examination, medical history, and vital signs performed at screening. Any abnormalities must be consistent with the underlying illness in the study population. This determination must be recorded in the participant's source documents and initialed by the investigator
  • Have a body mass index (BMI) between 18.0 and 35.0 kilograms per meter square (kg/m^2) inclusive (BMI = weight/height^2)
  • A woman of childbearing potential (WOCBP) must have a negative highly sensitive serum pregnancy test (beta-human chorionic gonadotropin [beta-hCG]) at screening and a negative urine pregnancy test before the first dose of study intervention

Exclusion Criteria:

  • Currently meets the DSM-5 criteria for Manic Episode (ME) on the MINI
  • Received transcranial magnetic stimulation (TMS), any transcranial electrical stimulation, including transcranial direct current stimulation (tDCS), vagal nerve stimulation (VNS) and/or deep brain stimulation (DBS) within 6 weeks prior to randomization
  • History of moderate to severe cannabis misuse according to DSM-5 criteria within 6 months before screening
  • History of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator is considered cured with minimal risk of recurrence)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05328297


Locations
Show Show 44 study locations
Sponsors and Collaborators
Janssen Pharmaceutica N.V., Belgium
Investigators
Layout table for investigator information
Study Director: Janssen Pharmaceutica N.V., Belgium Clinical Trial Janssen Pharmaceutica N.V., Belgium
Layout table for additonal information
Responsible Party: Janssen Pharmaceutica N.V., Belgium
ClinicalTrials.gov Identifier: NCT05328297    
Other Study ID Numbers: CR109116
2021-004790-31 ( EudraCT Number )
55308942BIP2001 ( Other Identifier: Janssen Pharmaceutica N.V., Belgium )
First Posted: April 14, 2022    Key Record Dates
Last Update Posted: May 22, 2024
Last Verified: May 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
URL: https://www.janssen.com/clinical-trials/transparency

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Bipolar Disorder
Bipolar and Related Disorders
Mood Disorders
Mental Disorders
JNJ-55308942
Purinergic P2X Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs